Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VGX terminates HIV drug development program
The company’s decision is based on the following: lack of clinically significant antiviral effects at the doses tested to date as a single therapy; and availability of very
The company’s decision is based on the following: lack of clinically significant antiviral effects at the doses tested to date as a single therapy; and availability of very
Under the terms of the agreement, InSight will provide magnetic resonance imaging services at four County-owned academic medical centers: Harbor-UCLA, Martin Luther King, Jr/Drew Medical Center, Olive View-UCLA
The parties expect to complete the merger in the fourth quarter of 2008, however, the actual timing of the transaction will depend on a number of factors, some
In addition, Digestive Care has recently completed a randomized, double-blind, placebo-controlled, multi-center, crossover study on Pancrecarb MS-16. The clinical trial was conducted at five centers and included 21
Cognitive function was significantly improved over placebo (p=0.03) as measured by the mini-mental state examination (MMSE), the cognition scale most widely used by clinicians to assess patients with
In addition, St Jude Medical announced the final allocation of cash and stock to EP MedSystems shareholders in connection with the acquisition. As previously announced, under the terms
The company expects Mr Freiman to continue to serve on the board. Mr Freiman is the former CEO of Syntex of Palo Alto, California. Mr Freiman is retiring
Mr Prentki succeeds Gregory Turnbull, who will remain a company director, a member of the board’s executive committee and, until a permanent successor is recruited, interim CFO. Mr
Under its agreement with Recordati to reacquire the UK rights to its once-daily tramadol product, Labopharm will continue to use the brand name Tradorec XL in marketing its
Additional subjects are being evaluated for eligibility for entrance into the trial or are awaiting treatment at the two active centers in Brisbane and Sydney, Australia. In addition,